TERM ID="NYU_TERM_1" STRING="(HER2)-positive metastatic adenocarcinoma" FREQUENCY=1 START=270 END=311 LEMMA="(HER2)-POSITIVE METASTATIC ADENOCARCINOMA" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_2" STRING="CF" FREQUENCY=1 START=2088 END=2090 LEMMA="CYSTIC FIBROSIS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_3" STRING="CX/F dose" FREQUENCY=1 START=2194 END=2203 LEMMA="CX/F DOSE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_4" STRING="ECF" FREQUENCY=2 START=1806 END=1809 LEMMA="EPIRUBICIN, CISPLATIN, 5 FU" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_5" STRING="ECF" FREQUENCY=2 START=2459 END=2462 LEMMA="EPIRUBICIN, CISPLATIN, 5 FU" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_6" STRING="ECX" FREQUENCY=3 START=1728 END=1731 LEMMA="ECX" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_7" STRING="ECX" FREQUENCY=3 START=2446 END=2449 LEMMA="ECX" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_8" STRING="ECX" FREQUENCY=3 START=3153 END=3156 LEMMA="ECX" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_9" STRING="ECX/ECF/EOX" FREQUENCY=1 START=3766 END=3777 LEMMA="ECX/ECF/EOX" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_10" STRING="EOX" FREQUENCY=4 START=1772 END=1775 LEMMA="EPIRUBICIN, OXALIPLATIN," LEMMA_FREQUENCY=5
TERM ID="NYU_TERM_11" STRING="EOX" FREQUENCY=4 START=2451 END=2454 LEMMA="EPIRUBICIN, OXALIPLATIN," LEMMA_FREQUENCY=5
TERM ID="NYU_TERM_12" STRING="EOX" FREQUENCY=4 START=3385 END=3388 LEMMA="EPIRUBICIN, OXALIPLATIN," LEMMA_FREQUENCY=5
TERM ID="NYU_TERM_13" STRING="EOX" FREQUENCY=4 START=3475 END=3478 LEMMA="EPIRUBICIN, OXALIPLATIN," LEMMA_FREQUENCY=5
TERM ID="NYU_TERM_14" STRING="EOX replaced ECX" FREQUENCY=1 START=3385 END=3401 LEMMA="REPLACED ECX EPIRUBICIN, OXALIPLATIN," LEMMA_FREQUENCY=1 HEAD_TERM="replaced ECX" HEAD_LEMMA="REPLACED ECX"
TERM ID="NYU_TERM_15" STRING="FISH" FREQUENCY=1 START=469 END=473 LEMMA="FLUORESCENCE IN SITU HYBRIDISATION" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_16" STRING="HCF" FREQUENCY=1 START=2415 END=2418 LEMMA="HCX OR TRASTUZUMAB, CISPLATIN, 5 FU" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_17" STRING="HCX" FREQUENCY=4 START=741 END=744 LEMMA="HCX" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_18" STRING="HCX" FREQUENCY=4 START=2378 END=2381 LEMMA="HCX" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_19" STRING="HCX" FREQUENCY=4 START=3142 END=3145 LEMMA="HCX" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_20" STRING="HCX" FREQUENCY=4 START=3468 END=3471 LEMMA="HCX" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_21" STRING="HCX or trastuzumab, cisplatin, 5-FU" FREQUENCY=1 START=2378 END=2413 LEMMA="HCX OR TRASTUZUMAB, CISPLATIN, 5-FU" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_22" STRING="HCX/F" FREQUENCY=4 START=1014 END=1019 LEMMA="HCX/F" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_23" STRING="HCX/F" FREQUENCY=4 START=1098 END=1103 LEMMA="HCX/F" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_24" STRING="HCX/F" FREQUENCY=4 START=1641 END=1646 LEMMA="HCX/F" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_25" STRING="HCX/F" FREQUENCY=4 START=3899 END=3904 LEMMA="HCX/F" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_26" STRING="HER2 positivity" FREQUENCY=1 START=365 END=380 LEMMA="HER2 POSITIVITY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_27" STRING="HER2 status populations" FREQUENCY=1 START=1505 END=1528 LEMMA="HER2 STATUS POPULATION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_28" STRING="HER2 testing" FREQUENCY=1 START=2781 END=2793 LEMMA="HER2 TESTING" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_29" STRING="HER2-positive mGC population" FREQUENCY=1 START=1424 END=1452 LEMMA="HER2-POSITIVE MGC POPULATION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_30" STRING="HER2-positive metastatic adenocarcinoma" FREQUENCY=1 START=33 END=72 LEMMA="HER2-POSITIVE METASTATIC ADENOCARCINOMA" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_31" STRING="HER2-positive patients" FREQUENCY=1 START=627 END=649 LEMMA="HER2-POSITIVE PATIENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_32" STRING="ICER" FREQUENCY=3 START=3111 END=3115 LEMMA="INCREMENTAL COST EFFECTIVENESS RATIO" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_33" STRING="ICER" FREQUENCY=3 START=3441 END=3445 LEMMA="INCREMENTAL COST EFFECTIVENESS RATIO" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_34" STRING="ICER" FREQUENCY=3 START=3955 END=3959 LEMMA="INCREMENTAL COST EFFECTIVENESS RATIO" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_35" STRING="IHC" FREQUENCY=1 START=557 END=560 LEMMA="IMMUNOHISTOCHEMISTRY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_36" STRING="IHC2" FREQUENCY=2 START=427 END=431 LEMMA="IHC2" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_37" STRING="IHC2" FREQUENCY=2 START=570 END=574 LEMMA="IHC2" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_38" STRING="NHS" FREQUENCY=4 START=833 END=836 LEMMA="NHS" LEMMA_FREQUENCY=4 HEAD_TERM="NHS" HEAD_LEMMA="NHS" TERM_PATTERN_TYPE="chemical"
TERM ID="NYU_TERM_39" STRING="NHS" FREQUENCY=4 START=1678 END=1681 LEMMA="NHS" LEMMA_FREQUENCY=4 HEAD_TERM="NHS" HEAD_LEMMA="NHS" TERM_PATTERN_TYPE="chemical"
TERM ID="NYU_TERM_40" STRING="NHS" FREQUENCY=4 START=2681 END=2684 LEMMA="NHS" LEMMA_FREQUENCY=4 HEAD_TERM="NHS" HEAD_LEMMA="NHS" TERM_PATTERN_TYPE="chemical"
TERM ID="NYU_TERM_41" STRING="NHS" FREQUENCY=4 START=3927 END=3930 LEMMA="NHS" LEMMA_FREQUENCY=4 HEAD_TERM="NHS" HEAD_LEMMA="NHS" TERM_PATTERN_TYPE="chemical"
TERM ID="NYU_TERM_42" STRING="NHS perspective" FREQUENCY=1 START=2681 END=2696 LEMMA="NHS PERSPECTIVE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_43" STRING="NHS therapy" FREQUENCY=2 START=833 END=844 LEMMA="NHS THERAPY" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_44" STRING="NHS therapy" FREQUENCY=2 START=1678 END=1689 LEMMA="NHS THERAPY" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_45" STRING="QALY" FREQUENCY=2 START=3133 END=3137 LEMMA="QUALITY ADJUSTED LIFE YEAR" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_46" STRING="QALY" FREQUENCY=2 START=3526 END=3530 LEMMA="QUALITY ADJUSTED LIFE YEAR" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_47" STRING="QALY for HCX" FREQUENCY=1 START=3133 END=3145 LEMMA="HCX QUALITY ADJUSTED LIFE YEAR" LEMMA_FREQUENCY=1 HEAD_TERM="QALY" HEAD_LEMMA="QUALITY ADJUSTED LIFE YEAR"
TERM ID="NYU_TERM_48" STRING="QALYs" FREQUENCY=1 START=2645 END=2650 LEMMA="QUALITY ADJUSTED LIFE YEARS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_49" STRING="RCT" FREQUENCY=1 START=995 END=998 LEMMA="RANDOMISED CONTROLLED TRIAL" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_50" STRING="RCTs comparing epirubicin-containing triplets" FREQUENCY=1 START=2020 END=2065 LEMMA="RCTS COMPARING EPIRUBICIN-CONTAINING TRIPLET" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_51" STRING="Trastuzumab" FREQUENCY=1 START=0 END=11 LEMMA="TRASTUZUMAB" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_52" STRING="Utility weights" FREQUENCY=1 START=2575 END=2590 LEMMA="UTILITY WEIGHT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_53" STRING="alternative model assumptions" FREQUENCY=1 START=3242 END=3271 LEMMA="ALTERNATIVE MODEL ASSUMPTION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_54" STRING="base-case analyses" FREQUENCY=1 START=3334 END=3352 LEMMA="BASE-CASE ANALYSIS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_55" STRING="capecitabine" FREQUENCY=6 START=702 END=714 LEMMA="CAPECITABINE" LEMMA_FREQUENCY=6
TERM ID="NYU_TERM_56" STRING="capecitabine" FREQUENCY=6 START=770 END=782 LEMMA="CAPECITABINE" LEMMA_FREQUENCY=6
TERM ID="NYU_TERM_57" STRING="capecitabine" FREQUENCY=6 START=1076 END=1088 LEMMA="CAPECITABINE" LEMMA_FREQUENCY=6
TERM ID="NYU_TERM_58" STRING="capecitabine" FREQUENCY=6 START=1714 END=1726 LEMMA="CAPECITABINE" LEMMA_FREQUENCY=6
TERM ID="NYU_TERM_59" STRING="capecitabine" FREQUENCY=6 START=1758 END=1770 LEMMA="CAPECITABINE" LEMMA_FREQUENCY=6
TERM ID="NYU_TERM_60" STRING="capecitabine" FREQUENCY=6 START=2092 END=2104 LEMMA="CAPECITABINE" LEMMA_FREQUENCY=6
TERM ID="NYU_TERM_61" STRING="cisplatin" FREQUENCY=8 START=681 END=690 LEMMA="CISPLATIN" LEMMA_FREQUENCY=8
TERM ID="NYU_TERM_62" STRING="cisplatin" FREQUENCY=8 START=759 END=768 LEMMA="CISPLATIN" LEMMA_FREQUENCY=8
TERM ID="NYU_TERM_63" STRING="cisplatin" FREQUENCY=8 START=1025 END=1034 LEMMA="CISPLATIN" LEMMA_FREQUENCY=8
TERM ID="NYU_TERM_64" STRING="cisplatin" FREQUENCY=8 START=1065 END=1074 LEMMA="CISPLATIN" LEMMA_FREQUENCY=8
TERM ID="NYU_TERM_65" STRING="cisplatin" FREQUENCY=8 START=1703 END=1712 LEMMA="CISPLATIN" LEMMA_FREQUENCY=8
TERM ID="NYU_TERM_66" STRING="cisplatin" FREQUENCY=8 START=1789 END=1798 LEMMA="CISPLATIN" LEMMA_FREQUENCY=8
TERM ID="NYU_TERM_67" STRING="cisplatin" FREQUENCY=8 START=2071 END=2080 LEMMA="CISPLATIN" LEMMA_FREQUENCY=8
TERM ID="NYU_TERM_68" STRING="cisplatin" FREQUENCY=8 START=2398 END=2407 LEMMA="CISPLATIN" LEMMA_FREQUENCY=8
TERM ID="NYU_TERM_69" STRING="comparator" FREQUENCY=1 START=3421 END=3431 LEMMA="COMPARATOR" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_70" STRING="confidence interval" FREQUENCY=1 START=1255 END=1274 LEMMA="CONFIDENCE INTERVAL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_71" STRING="containing epirubicin" FREQUENCY=1 START=3743 END=3764 LEMMA="CONTAINING EPIRUBICIN" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_72" STRING="controlled trial" FREQUENCY=1 START=977 END=993 LEMMA="CONTROLLED TRIAL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_73" STRING="de novo economic evaluation" FREQUENCY=1 START=2296 END=2323 LEMMA="DE NOVO ECONOMIC EVALUATION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_74" STRING="decision problem" FREQUENCY=1 START=481 END=497 LEMMA="DECISION PROBLEM" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_75" STRING="doublet CX/F regimens" FREQUENCY=1 START=3783 END=3804 LEMMA="DOUBLET CX/F REGIMEN" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_76" STRING="economic model" FREQUENCY=1 START=2338 END=2352 LEMMA="ECONOMIC MODEL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_77" STRING="epidermal growth factor receptor" FREQUENCY=1 START=235 END=267 LEMMA="EPIDERMAL GROWTH FACTOR RECEPTOR" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_78" STRING="epirubicin" FREQUENCY=3 START=1691 END=1701 LEMMA="EPIRUBICIN" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_79" STRING="epirubicin" FREQUENCY=3 START=1733 END=1743 LEMMA="EPIRUBICIN" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_80" STRING="epirubicin" FREQUENCY=3 START=1777 END=1787 LEMMA="EPIRUBICIN" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_81" STRING="epirubicin, cisplatin, 5-FU" FREQUENCY=1 START=1777 END=1804 LEMMA="EPIRUBICIN, CISPLATIN, 5-FU" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_82" STRING="epirubicin, oxaliplatin," FREQUENCY=1 START=1733 END=1757 LEMMA="EPIRUBICIN, OXALIPLATIN," LEMMA_FREQUENCY=5
TERM ID="NYU_TERM_83" STRING="evidence review group" FREQUENCY=1 START=156 END=177 LEMMA="EVIDENCE REVIEW GROUP" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_84" STRING="fluorescence in situ hybridisation" FREQUENCY=1 START=433 END=467 LEMMA="FLUORESCENCE IN SITU HYBRIDISATION" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_85" STRING="fluoropyrimidine" FREQUENCY=1 START=1041 END=1057 LEMMA="FLUOROPYRIMIDINE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_86" STRING="fluorouracil" FREQUENCY=1 START=784 END=796 LEMMA="FLUOROURACIL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_87" STRING="gastro-oesophageal junction" FREQUENCY=2 START=91 END=118 LEMMA="GASTRO-OESOPHAGEAL JUNCTION" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_88" STRING="gastro-oesophageal junction" FREQUENCY=2 START=336 END=363 LEMMA="GASTRO-OESOPHAGEAL JUNCTION" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_89" STRING="hazard ratio" FREQUENCY=1 START=1232 END=1244 LEMMA="HAZARD RATIO" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_90" STRING="immunohistochemistry (IHC)" FREQUENCY=1 START=395 END=421 LEMMA="IMMUNOHISTOCHEMISTRY (IHC)" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_91" STRING="implementation" FREQUENCY=1 START=3546 END=3560 LEMMA="IMPLEMENTATION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_92" STRING="incremental cost-effectiveness ratio" FREQUENCY=2 START=3073 END=3109 LEMMA="INCREMENTAL COST-EFFECTIVENESS RATIO" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_93" STRING="incremental cost-effectiveness ratio" FREQUENCY=2 START=3073 END=3109 LEMMA="INCREMENTAL COST-EFFECTIVENESS RATIO" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_94" STRING="interpreting non-significant results" FREQUENCY=1 START=1974 END=2010 LEMMA="INTERPRETING NON-SIGNIFICANT RESULT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_95" STRING="life-years" FREQUENCY=1 START=2633 END=2643 LEMMA="LIFE-YEAR" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_96" STRING="lifetime analysis" FREQUENCY=1 START=2890 END=2907 LEMMA="LIFETIME ANALYSIS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_97" STRING="mGC" FREQUENCY=1 START=328 END=331 LEMMA="MGC" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_98" STRING="mGC population" FREQUENCY=1 START=537 END=551 LEMMA="MGC POPULATION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_99" STRING="manufacturer" FREQUENCY=4 START=849 END=862 LEMMA="MANUFACTURER" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_100" STRING="manufacturer" FREQUENCY=4 START=1550 END=1563 LEMMA="MANUFACTURER" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_101" STRING="manufacturer" FREQUENCY=4 START=3037 END=3050 LEMMA="MANUFACTURER" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_102" STRING="manufacturer" FREQUENCY=4 START=3171 END=3183 LEMMA="MANUFACTURER" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_103" STRING="median survival" FREQUENCY=1 START=1307 END=1322 LEMMA="MEDIAN SURVIVAL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_104" STRING="meta-analysis" FREQUENCY=1 START=1956 END=1969 LEMMA="META-ANALYSIS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_105" STRING="monitoring costs" FREQUENCY=1 START=2735 END=2751 LEMMA="MONITORING COST" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_106" STRING="narrative synthesis" FREQUENCY=1 START=1891 END=1910 LEMMA="NARRATIVE SYNTHESIS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_107" STRING="network meta-analysis" FREQUENCY=1 START=1589 END=1610 LEMMA="NETWORK META-ANALYSIS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_108" STRING="oxaliplatin" FREQUENCY=1 START=1745 END=1756 LEMMA="OXALIPLATIN" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_109" STRING="population subgroup" FREQUENCY=1 START=1205 END=1224 LEMMA="POPULATION SUBGROUP" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_110" STRING="progression-free" FREQUENCY=1 START=2509 END=2525 LEMMA="PROGRESSION-FREE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_111" STRING="quality-adjusted life-years" FREQUENCY=1 START=2616 END=2643 LEMMA="QUALITY-ADJUSTED LIFE-YEAR" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_112" STRING="randomised controlled trial" FREQUENCY=1 START=966 END=993 LEMMA="RANDOMISED CONTROLLED TRIAL" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_113" STRING="relative treatment effects" FREQUENCY=1 START=2983 END=3009 LEMMA="RELATIVE TREATMENT EFFECT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_114" STRING="replaced ECX" FREQUENCY=1 START=3389 END=3401 LEMMA="REPLACED ECX" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_115" STRING="sensitivity analyses" FREQUENCY=1 START=3212 END=3232 LEMMA="SENSITIVITY ANALYSIS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_116" STRING="situ hybridisation" FREQUENCY=1 START=449 END=467 LEMMA="SITU HYBRIDISATION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_117" STRING="supportive care costs" FREQUENCY=1 START=2820 END=2841 LEMMA="SUPPORTIVE CARE COST" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_118" STRING="testing strategies" FREQUENCY=2 START=3014 END=3032 LEMMA="TESTING STRATEGY" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_119" STRING="testing strategies" FREQUENCY=2 START=3576 END=3594 LEMMA="TESTING STRATEGY" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_120" STRING="three-state cohort model" FREQUENCY=1 START=2483 END=2507 LEMMA="THREE-STATE COHORT MODEL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_121" STRING="time horizon" FREQUENCY=1 START=2853 END=2865 LEMMA="TIME HORIZON" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_122" STRING="trastuzumab" FREQUENCY=3 START=196 END=207 LEMMA="TRASTUZUMAB" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_123" STRING="trastuzumab" FREQUENCY=3 START=746 END=757 LEMMA="TRASTUZUMAB" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_124" STRING="trastuzumab" FREQUENCY=3 START=2385 END=2396 LEMMA="TRASTUZUMAB" LEMMA_FREQUENCY=4
